IMMUNEREGEN RESPONDS TO NATIONAL INSTITUTES OF HEALTH REQUEST FOR INFORMATION

Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO News), announced today that it will respond to a Request for Information (RFI) regarding the National Institutes of Health (NIH) Program on the Development of Medical Countermeasures to Chemical Threats. ImmuneRegen's response will present its proprietary drug, Radilex(TM), as a potential universal treatment for a wide range of chemical threats.

Yahoo News (http://biz.yahoo.com/prnews/050803/law097.html?.v=17)